Objective To compare the prognostic significance of follicular lymphoma international prognostic index (FLIPI) and FLIPI2 for follicular lymphoma (FL). Methods The clinical data of 107 newly diagnosed FL patients who were admitted to the Department of Hematology, Changhai Hospital, Naval Medical University (Second Military Medical University) from Nov. 16, 2007 to Jun. 1, 2019 were collected, of which 52 patients received rituximab combined chemotherapy and 55 patients received chemotherapy alone. All patients were stratified according to FLIPI and FLIPI2 scores, and the progress-free survival (PFS) rate was analyzed. Results The median age of the 107 FL patients was 53 (25-77) years. The 3- and 5-year PFS rates of the 107 patients were 83.8% and 74.9%, respectively. According to FLIPI scores, the 5-year PFS rates of low-risk (score 0-1), intermediate-risk (score 2), and high-risk (score ≥ 3) groups were 91.7%, 72.0%, and 50.4%, respectively (χ²=14.274, P<0.001); according to FLIPI2 scores, the 5-year PFS rates of low-risk (score 0-1), intermediate-risk (score 2), and high-risk (score ≥ 3) groups were 86.8%, 64.4%, and 39.0%, respectively (χ²=16.675, P<0.001). In the rituximab combined chemotherapy group, there was significant difference in the 5-year PFS rate according to the FLIPI2 prognostic scoring model (χ²=21.597, P<0.01). In the chemotherapy alone group, according to the FLIPI prognostic scoring model, the difference in 5-year PFS rate was significant (χ²=11.982, P=0.003). The 5-year PFS rates of low-, intermediate- and high-risk groups had significant differences for patients aged ≤ 60 years according to FLIPI and FLIPI2 scores (all P<0.01). In the group with rituximab combined chemotherapy and age ≤ 60 years, FLIPI2 performed well in risk stratification for FL patients, and the 5-year PFS rates of patients in the low-, intermediate- and high-risk groups were 95.2%, 87.5% and 50.0%, respectively (χ²=13.989, P<0.001). Conclusion FLIPI2 performs better in risk stratification for FL patients than FLIPI in the era of rituximab. Age is no longer a prognostic factor affecting PFS in FL patients.